Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial

Respiratory Medicine

Volumn 101, Issue 2, 2007, Pages 254-260

  Suri, Ranjan ^a   Metcalfe, Chris ^b   Wallis, Colin ^a   Bush, Andrew ^c  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical trial; Cystic fibrosis; Outcome measures

Indexed keywords

DEOXYRIBONUCLEASE; SODIUM CHLORIDE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; EXERCISE TOLERANCE; EXPERIMENTAL DESIGN; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WEIGHT GAIN;

CHILD; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; FORCED EXPIRATORY VOLUME; HUMANS; MAXIMAL MIDEXPIRATORY FLOW RATE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME; VITAL CAPACITY; WEIGHT GAIN;

EID: 33846147999     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.05.012     Document Type: Article

References (26)

1. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 122 (1993) 1-9
2. Elborn J.S., Shale D.J., and Britton J.R. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 46 (1991) 881-885
3. Ramsey B.W., and Boat T. Outcome measures for clinical trials in cystic fibrosis. J Pediatr 124 (1994) 177-192
4. McCoy K., Hamilton S., and Johnson C.A.C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung dusease. Chest 110 (1996) 889-895
5. Ramsey B.W., Pepe M.S., Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340 (1999) 23-30
6. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
7. Corey M., McLaughlin F.J., Williams M., and Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 41 (1988) 583-591
8. Kerem E., Reisman J., Canny G.J., Bentur L., Canny G., and Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326 (1992) 1187-1191
9. Huang N.N., Scidlow D.V., Szatrowski T.H., Palmer J., Laraya-Cuasay L.R., and Yeung W. Clinical features, survival rate and prognostic factors in young adults with cystic fibrosis. Am J Med 82 (1987) 871-877
10. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
11. Dakin C., Henry R., Field P., and Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 31 (2001) 436-442
12. Suri R., Metcalfe C., Lees B., et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 358 (2001) 1316-1321
13. Polgar G., and Promodhat V. Pulmonary function testing in children: techniques and standards (1971), WB Saunders Company, Philadelphia
14. American Thoracic Society. Standardization of spirometry. Am J Respir Crit Care Med 152 (1994) 1107-1136
15. Balfour-Lynn I.M., Prasad S.A., Laverty A., Whitehead B.F., and Dinwiddie R. A step in the right direction: assessing exercise tolerance in cystic fibrosis. Pediatr Pulmonol 25 (1998) 278-284
16. Gift A.G. Validation of a vertical visual analogue scale as a measure of clinical dyspnoea. Rehabil Nurs 14 (1989) 323-325
17. Adams L., Chronos N., Lane R., and Guz A. The measurement of breathlessness induced in normal subjects: validity of two scaling techniques. Clin Sci 69 (1985) 7-16
18. Orenstein D.M., Nixon P.A., Ross E.A., and Kaplan R.M. The quality of well-being in cystic fibrosis. Chest 95 (1989) 344-347
19. Fuchs H., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 331 (1994) 637-642
20. Diggle P.J., Liang K.Y., and Zeger S.L. Analysis of longitudinal data (1994), Oxford University Press, Oxford
21. Davison A.C., and Hinkley D.V. Bootstrap methods and their application (1997), Cambridge University Press, Cambridge
22. Kraemer R., Rudeberg A., Hadorn B., and Rossi E. Relative underweight in cystic fibrosis and its prognostic value. Acta Paediatr Scand 67 (1978) 33-37
23. Zemel B.S., Kawchak D.A., Cnaan A., Zhao H., Scanlin T.F., and Stallings V.A. Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function, and genotype in children with cystic fibrosis. Pediatr Res 40 (1996) 578-586
24. Prasad S.A., Randall S.D., and Balfour-Lynn I.M. Fifteen-count breathlessness score: an objective measure for children. Pediatr Pulmonol 30 (2000) 56-62
25. Quittner A.L., Sweeny S., Watrous M., et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Paediatr Psychol 25 (2000) 403-414
26. Cerny F.J., Cropp G.J., and Bye M.R. Hospital therapy improves exercise tolerance and lung function in cystic fibrosis. Am J Dis Child 138 (1984) 261-265